Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt

EU orphan designation number: EU/3/12/1036   
Active ingredient: Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt
Indication: Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia)
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/09/2012 Centralised Orphan - Designation EMA/OD/071/12 (2012)6514 of 14/09/2012
29/08/2014 Centralised Orphan - Change of address